Core Insights - Algeria is advancing its pharmaceutical sovereignty strategy, achieving significant progress in key areas such as insulin, anticancer drugs, and hormone medications, while gradually exporting domestically produced medicines to multiple African countries [1] Industry Development - The Algerian Ministry of Pharmaceutical Industry is focusing on expanding local production capacity and attracting global pharmaceutical companies' technologies, with health sovereignty as a core aspect of its industrial policy [1] - Algeria has established strategic partnerships with several leading international laboratories to acquire the latest innovations in pharmaceutical technology [1] Production Capacity - The country has approved 100 new pharmaceutical production projects, which will significantly enhance local production capabilities and improve the quality of domestically produced medicines [1] - Algeria currently has over 230 pharmaceutical companies and 780 production lines, indicating a robust growth in the pharmaceutical sector and reflecting the country's ambition to become a key pharmaceutical hub in Africa and the Mediterranean region [1]

Core Viewpoint - Algeria's government is enhancing its pharmaceutical industry by establishing new production facilities in the southern provinces to achieve self-sufficiency and ensure national drug supply [1] Group 1: New Production Facilities - The state-owned pharmaceutical group Saidal will build new drug production plants in the southern provinces of Ouled Djellal, Ouargla, and Tamanrasset [1] - The new factories aim to decentralize production and better meet regional demands while strengthening industrial development in the south [1] Group 2: Economic and Employment Impact - The initiative is expected to create job opportunities and promote economic development in the inland and southern provinces [1] - Collaboration with the Algerian Investment Promotion Agency will support the development of pharmaceutical projects utilizing local land resources [1] Group 3: Local Production Goals - Plans include the local production of key pharmaceutical raw materials, covering diabetes medications, cancer drugs, heart disease treatments, and antibiotics [1] - Some strategic projects are anticipated to commence production by the end of 2026, with local production of dental anesthetics starting next year to address supply shortages [1] Group 4: Overall Objectives - The overarching goals are to enhance the autonomy of the pharmaceutical industry, reduce reliance on imports, ensure drug supply, and promote balanced economic development across regions [1]